This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Spectrum Blames Fusilev Sales Warning on Overstuffed Inventory

Stocks in this article: SPPI

HENDERSON, Nev. ( TheStreet) -- Spectrum Pharmaceuticals (SPPI - Get Report) retreated to the cosy confines of a private conference call with Wall Street investors Wednesday morning to attempt damage control for last night's massive Fusilev sales warning.

Investor confidence in Spectrum and its CEO Raj Shrotriya -- already tenuous -- is now in tatters. Shrotriya has always been quick to promote the company through press releases and public conference calls when it suits him. But when a detailed explanation of bad news is warranted, Shrotriya shows disdain for his broader shareholder base by speaking only to a select group of investors on a call organized by the investment bank Credit Suisse.

Spectrum shares are down 36% to $7.90 in early Wednesday trading.

For those that may have missed the details of last night's Fusilev warning, Spectrum said it expects sales in the first quarter to be between $10 million and $15 million. That's down sharply from $44.6 million in sales recorded in the December quarter. For all of 2013, Spectrum expects Fusilev sales of just $80 million to $90 million, well off 2012 sales of $204 million.

Spectrum's walk back of Fusilev sales on Tuesday night came just three weeks after the company's year-end earnings call, on which Shrotriya promised sales growth for 2013. Shrotriya boasted about Fusilev growth despite flat revenue for the past three quarters.

"We expect with the trends we are seeing in January, and we are seeing the new accounts and the reorders from the old accounts, that we expect that 2013 revenues to continue to grow. And we expect our sales to be higher than we had in 2012," Shrotriya said on the Feb. 21 call.

What happened in the past three weeks to radically change the outlook for Fusilev?

On the Credit Suisse call, Spectrum COO Ken Keller offered two causes: 1) Three of the four largest wholesalers only recently informed Spectrum they would not be purchasing any Fusilev in the first quarter. These wholesalers had enough Fusilev on their shelves already to meet user demand, and they were "watching market dynamics" before buying additional supply. 2) Hospital use of Fusilev, already in decline due to switching back to generic leucovorin, was decelerating faster than Spectrum had originally projected.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs